Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. View the ESS Brochure here

Join us at the next event, or view this blog for past events.

ESS Free Webinar On Chosen Science: June 27

The Emerging Science™ Series presents chosen science submissions in a free webinar

Date: June 27, 2011
Time: 12-1:05 p.m. Central Time(USA) :UTC/GMT -5


Register for the webinar at: scientificsessions.org/emergingscience



 
Presentation Topics:

1. First Human Use of an Allogeneic Tissue Engineered Vascular Graft
Description: A first-in-human study to test the feasibility of an allogeneic tissue-engineered vascular graft. 
Presenter: Todd N. McAllister, Novato, Calif.
 
2. Ticagrelor Compared with Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Description: Presentation of the regional variation in outcomes in PLATO with an emphasis on the North American cohort.
Presenter: Kenneth W. Mahaffey, Durham, N.C.


Moderators: Timothy J. Gardner, Elliott Antman, and Robert Harrington


Panelists: Donna Arnett, Eric R. Bates, Conville Brown, and Frank Sellke
 

 
 
Posted by Elliott Antman on Jun 7, 2011 11:21 AM America/Chicago

Leave a Comment

After you register, be sure to <A href="http://networking.americanheart.org/events/item/11/88">RSVP</A> on the Professional Online Network to let others know you are attending! <BR><BR><A href="http://networking.americanheart.org/events/item/11/88">RSVP now!</A><BR><BR>
  • Posted Wed 08 Jun 2011 11:29 AM CDT
I am especially excited about this inaugural webinair for the AHA Emerging Science Series. Viewers will see a presentation of a translational science project where investigators report the first in human application of tissue engineered vascular grafts. This has great potential for transforming the surgical approach to vascular grafting. The second presentation is a fascinating analysis from an important new antiplatelet agent ---the US subgroup findings from the PLATO study. This will generate interesting discussion about the interpretation of subgroups from clinical trials and drug interactions between antiplatelet agents.
  • Posted Mon 13 Jun 2011 10:53 AM CDT
This novel venue for presenting the latest science is a wonderful extension of the efforts of CSSP, to deliver the best science in the cardiovascular community year-round under the banner of the AHA.
  • Posted Mon 13 Jun 2011 01:54 PM CDT
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.
  • Posted Tue 14 Jun 2011 11:37 AM CDT
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
  • Posted Tue 14 Jun 2011 12:58 PM CDT
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
  • Posted Wed 15 Jun 2011 11:52 AM CDT
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
  • Posted Wed 15 Jun 2011 03:01 PM CDT

Log in to post a comment.

Login or Join

Login or Join to post a comment.

Comments

Login or Join

You must be logged in to comment on blogs.

Login using your My.AmericanHeart credentials:


Don't have an account?

Share With Colleagues:

Share with colleagues:

Login to Post

You must be logged in to comment on blogs.

Login using your My.AmericanHeart credentials:


Don't have an account?